Baloxavir Marboxil Treatment of Nude Mice Infected With Influenza A Virus

• Published in: The Journal of infectious diseases Vol. 221; no. 10; pp. 1699 - 1702
• Main Authors: Kiso, Maki, Yamayoshi, Seiya, Murakami, Jurika, Kawaoka, Yoshihiro
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 27.04.2020
• Subjects: Animals; Antiviral Agents - administration & dosage; Antiviral Agents - therapeutic use; Antiviral drugs; Body weight; Body weight loss; Dibenzothiepins - administration & dosage; Dibenzothiepins - therapeutic use; Dose-Response Relationship, Drug; Drug resistance; Exo-a-sialidase; Immunocompromised hosts; Influenza; Influenza A; Influenza A virus; Major and Brief Reports; Male; Mice; Mice, Nude; Morpholines - administration & dosage; Morpholines - therapeutic use; Orthomyxoviridae Infections - drug therapy; Orthomyxoviridae Infections - veterinary; Orthomyxoviridae Infections - virology; Pyridones - administration & dosage; Pyridones - therapeutic use; Resistant mutant; Respiratory organs; Respiratory tract; Triazines - administration & dosage; Triazines - therapeutic use; Viruses; influenza; baloxavir marboxil; drug resistance; immunocompromised
• DOI: 10.1093/infdis/jiz665
• ISSN: 0022-1899; 1537-6613

Abstract Background Immunocompromised patients infected with influenza virus require prolonged treatment with neuraminidase inhibitors, because these patients are not able to eradicate the virus from the respiratory tract, leading to the emergence of drug-resistant mutant viruses. Methods In this study, we examined the efficacy of baloxavir marboxil in nude mice that were immunologically deficient. Results Daily treatment with a suboptimal dose of baloxavir marboxil increased the survival time of the virus-infected nude mice but did not clear the virus from their respiratory organs, resulting in gradual body weight loss after termination of treatment. Conclusions Despite the prolonged baloxavir marboxil treatment, few resistant mutants were detected.